AZN Stock Price Today (September 2026) — AstraZeneca PLC Analysis & Key Metrics 2026-09-04
AstraZeneca PLC (AZN) is trading at $162.70, down 1.26% today (as of September 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $212.54 (30.6% upside).
- Volatility remains elevated (19.49% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.40% YoY) alongside significant competitive pressures.
AZN Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
AstraZeneca PLC - Historical Price & Volume
Market Cap
Enterprise Value: $279.80B
P/E Ratio
Forward P/E: 14.27
Revenue Growth
Year over Year
Analyst Target
+30.6% upside potential
Key Investor Questions About AZN
What investors need to know before buying
Based on current market data, AZN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 47.29)
- Fundamentals say: Caution warranted (high leverage concerns)
AZN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AZN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $32.35B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AZN stock traded between $145.80 and $212.71—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.49% annualized volatility and β=0.37, the stock exhibits low sensitivity to market moves—making AZN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Haleon And 2 British AI Healthcare Stocks To Watch
With UK gilt yields responding to shifting Bank of England expectations, investors are rethinking where dependable long term growth could come from. Healthcare companies using artificial intelligence to improve diagnosis and treatment sit at the crossroads of technology and essential services, which can matter when borrowing costs and inflation concerns move in and out of focus. This article highlights three UK listed AI healthcare stocks from our screener to put on your radar. The stocks...
AstraZeneca Wins FDA Accelerated Approval for Breast Cancer Drug Etcamah
Astrazeneca (AZN) said Friday the FDA granted accelerated approval to its drug Etcamah, camizestrant
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power
AMD, Costco and AstraZeneca headline Zacks' latest research, with AI demand, membership strength and new drugs shaping their outlooks.
TEZSPIRE’s Positive EoE Phase 3 Results Could Be A Game Changer For Amgen (AMGN)
Amgen and AstraZeneca recently reported positive Phase 3 CROSSING results showing TEZSPIRE improved histologic remission and dysphagia symptoms in patients with eosinophilic esophagitis, with effects sustained through week 52 and a safety profile broadly consistent with prior use. Because EoE remains poorly controlled for nearly half of patients on existing therapies, TEZSPIRE’s epithelial-targeting mechanism could meaningfully expand its role beyond severe asthma and nasal polyps if...
Top Stock Reports for AMD, Costco & AstraZeneca
AMD, Costco and AstraZeneca headline today's stock reports, with AI demand, membership growth and drug pipelines shaping their outlooks.
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.
Explore More Analysis for AZN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about AstraZeneca PLC
AstraZeneca PLC (AZN) is currently trading at $162.70. The RSI (14-day) is at 47.3, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $212.54 implies 30.6% upside from current levels. Volatility is low at 19.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AstraZeneca PLC (AZN): The trailing P/E ratio is 24.32, which is in line with broader market averages. The forward P/E is 14.27, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.42, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 5.02. Price-to-Sales is 4.11. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering AZN, the consensus price target is $212.54. This represents a 30.6% upside from the current price of $162.70. The range spans from a low target of $184.00 to a high target of $240.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AstraZeneca PLC (AZN) pays a dividend with a current yield of approximately 1.97%. The annualized dividend rate is $3.23 per share. The payout ratio is 47.4%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-07T00:00:00.000Z.
Key risks for AstraZeneca PLC (AZN) investors include: 1. Elevated short interest (12.0% of float) suggests significant bearish sentiment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AstraZeneca PLC's (AZN) current debt and financial health profile: Total debt stands at $32.35B. The debt-to-equity ratio is 64.22, which is moderate and generally manageable for most companies. The current ratio is 0.89, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.66. The company holds $4.97B in cash and equivalents. Free cash flow is positive at $4.91B, providing a cushion for debt servicing and shareholder returns.